DalsnaFinance

Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease

Markets PR Newswire By PR Newswire 30 Jun 2026 11:00 1 min read
Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease

Twelve-month findings showed favorable and consistent trends for participants receiving SKY-0515 across all four cUHDRS subcomponents, including Total Functional Capacity (TFC), Total Motor Score (TMS), Symbol Digit Modalities Test (SDMT), and Stroop Word Reading Test (SWRT) Skyhawk also...

Twelve-month findings showed favorable and consistent trends for participants receiving SKY-0515 across all four cUHDRS subcomponents, including Total Functional Capacity (TFC), Total Motor Score (TMS), Symbol Digit Modalities Test (SDMT), and Stroop Word Reading Test (SWRT) Skyhawk also...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.